|
|
Pipeline
 |
 |
 |
 |
 |
 |
 |
 |
| ONCOLOGY |
| Tivantinib (ARQ 197)7 |
C-Met Inhibitor |
Daiichi Sankyo4
Kyowa Hakko5 |
|
|
|
|
|
| ARQ 621 |
Eg5 Inhibitor |
|
|
|
|
|
|
| ARQ 736 |
BRAF Inhibition |
|
|
|
|
|
|
| ARQ 087 |
FGFR Inhibition |
|
|
|
|
|
|
| ARQ 092 |
AKT Inhibitor |
Daiichi Sankyo6 |
|
|
|
|
|
|
Portfolio Updated February 2012
1 Pre-GLP toxicology testing
2 Post-initiation of GLP toxicology testing
3 Designation follows initation of first patient enrollment and dosing in lead indication
4 U.S., Europe, South America and the rest of the world, excluding Japan and select Asian countries
5 Japan and select Asian countries
6 Multiple targets in oncology are the subject of a collaboration based on the ArQule Kinase Inhibitor Platform (AKIPTM)
7 See corporate slide presentation here for the status of all ongoing trials with ARQ 197.
|
|
